−1.19SEK
−39.81 MSEK
10.11 MSEK
25.25 M
About NEXTCELL PHARMA AB
Sector
CEO
Mathias Svahn
Headquarters
Huddinge
Website
Founded
2014
ISIN
SE0009723125
FIGI
BBG00GQQ3RY8
NextCell Pharma AB engages in the development of stem cell products. It specializes in the treatment of diabetes and immunosuppression in kidney transplants. The company was founded by Mathias Svahn, Edvard Smith, Hans-Peter Torsten Ekre, and Lena Degling Wilkingsson on March 19, 2014 and is headquartered in Huddinge, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NXTCL is 1.33 SEK — it has decreased by 44.58% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange NEXTCELL PHARMA AB stocks are traded under the ticker NXTCL.
NXTCL stock is 95.12% volatile and has beta coefficient of 0.82. Check out the list of the most volatile stocks — is NEXTCELL PHARMA AB there?
Yes, you can track NEXTCELL PHARMA AB financials in yearly and quarterly reports right on TradingView.
NXTCL stock has fallen by 53.17% compared to the previous week, the month change is a 58.70% fall, over the last year NEXTCELL PHARMA AB has showed a 78.55% decrease.
NXTCL net income for the last quarter is −9.80 M SEK, while the quarter before that showed −8.64 M SEK of net income which accounts for −13.37% change. Track more NEXTCELL PHARMA AB financial stats to get the full picture.
Today NEXTCELL PHARMA AB has the market capitalization of 82.51 M, it has decreased by 9.15% over the last week.
No, NXTCL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NXTCL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEXTCELL PHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEXTCELL PHARMA AB technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEXTCELL PHARMA AB stock shows the strong sell signal. See more of NEXTCELL PHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEXTCELL PHARMA AB EBITDA is −45.10 M SEK, and current EBITDA margin is −438.59%. See more stats in NEXTCELL PHARMA AB financial statements.